कंपनी का अवलोकन
InfuSystem Holdings, Inc. operates primarily within the healthcare sector, specifically focusing on the medical devices industry by manufacturing and supplying electronic ambulatory infusion pumps along with related disposable products and services. This specialized positioning allows the firm to serve a critical niche in patient care and clinical environments across the United States and Canada. The company maintains a substantial operational scale, employing a workforce of 461 individuals to support its manufacturing and distribution networks. In terms of market valuation, InfuSystem Holdings, Inc. commands a market capitalization of $195.63M, supported by an annual revenue stream of $143.44M generated over the trailing twelve-month period. These financial metrics collectively indicate that the company holds a significant position in its segment, possessing sufficient revenue base to fund operations while maintaining a valuation that reflects investor expectations for growth within the medical technology landscape.
वित्तीय स्वास्थ्य
The company reported total revenue of $143.44M for the trailing twelve months, with a corresponding net income of $6.63M and an EBITDA of $24.11M, illustrating a distinct gap between top-line revenue and bottom-line earnings that highlights the substantial cost structure associated with manufacturing and operational expenses. This cost structure further demonstrates that while gross profitability is maintained, operating costs significantly impact the final net profit available to shareholders. The firm generated free cash flow of $14.83M, which signifies a robust capacity to generate liquidity from core business activities and provides essential financial flexibility for capital allocation decisions. Profitability is analyzed through three key margins: a gross margin of 56.0%, an operating margin of 4.7%, and a profit margin of 4.6%. The gross margin indicates efficient production and pricing power, whereas the operating and profit margins reveal that a considerable portion of revenue is consumed by operating expenses before reaching the net income level. Regarding leverage, the company holds cash reserves of $3.19M against total debt of $24.44M, resulting in a debt-to-equity ratio of 42.63. This specific balance sheet composition suggests a leveraged position where debt obligations exceed cash on hand, though the overall leverage must be viewed in the context of the firm's asset base and earnings generation capabilities. Liquidity analysis shows a current ratio of 1.80, which indicates that the company possesses 1.80 dollars in current assets for every dollar of current liabilities, suggesting a comfortable short-term liquidity position to meet its obligations. Furthermore, return metrics reveal an ROE of 11.5% and an ROA of 6.7%, which provide insight into management's effectiveness in generating returns on shareholders' equity and utilizing total assets to produce profits respectively.
मूल्यांकन आकलन
Valuation multiples for InfuSystem Holdings, Inc. include a P/E Ratio (TTM) of 31.03 and a Forward P/E of 33.17, where the higher forward multiple implies that the market expects earnings growth to outpace current performance levels in the coming periods. The price-to-book ratio stands at 3.39, indicating that the stock trades at a significant premium relative to its tangible book value, which often reflects market optimism regarding intangible assets, growth potential, or brand strength in the medical device sector. Alternative valuation metrics such as the price-to-sales ratio of 1.36 and an EV/EBITDA of 8.95 offer additional perspectives on value, suggesting that the company is priced based on a combination of revenue generation and cash flow generation relative to enterprise value. Historical price volatility is contextualized by a 52-week high of $11.04 and a 52-week low of $4.66, providing a range within which the stock price has fluctuated over the past year. The beta value of 1.55 indicates that the stock exhibits higher price volatility relative to the broader market, meaning the stock tends to move more aggressively than the market index during periods of equity market fluctuations.
Growth & Income
Growth metrics demonstrate a Revenue Growth (YoY) of 7.0% and an Earnings Growth (YoY) of 123.9%, revealing that earnings are expanding at a rate significantly faster than revenue. This disparity often implies that the company is benefiting from operational efficiencies, margin expansion, or one-time gains that disproportionately impact the net income figure compared to the top line. Regarding income distribution, the company currently does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This policy indicates that the company retains all of its net income to reinvest into business expansion, research and development, or debt reduction rather than distributing cash to shareholders. The overall growth and income profile is characterized by strong earnings acceleration and a capital retention strategy, positioning the firm to potentially utilize future cash flows for internal growth initiatives or potential shareholder returns in the future.